Примери за използване на Thiotepa на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The active substance is thiotepa.
Thiotepa is a highly lipophilic compound.
One vial contains 15 mg thiotepa.
Thiotepa appears to be metabolised via CYP2B6 and CYP3A4.
There is no known antidote for thiotepa.
Therefore, thiotepa is contraindicated during pregnancy.
Specific interactions with thiotepa.
The total clearance of thiotepa ranged from 11.4 to 23.2 l/h/m2.
There is no experience with overdoses of thiotepa.
Thiotepa, belongs to a group of medicines called‘alkylating agents'.
Each ml contains 10 mg thiotepa(10 mg/ml).
Treosulfan is given in combination with fludarabine with or without thiotepa.
Engraftment: Conditioning treatments including thiotepa have proved to be myeloablative.
It has been achieved with all reported conditioning regimens including thiotepa.
As most alkylating agents, thiotepa might impair male and female fertility.
Topical reactions associated with accidental exposure to thiotepa may occur.
Urinary excretion of thiotepa and TEPA is nearly complete after 6 and 8 hours respectively.
After reconstitution with 1.5 ml of water for injection,each ml contains 10 mg thiotepa.
The administration of thiotepa has not been specifically investigated in elderly patients.
Renal impairment The effects of renal impairment on thiotepa elimination have not been assessed.
This medicine is used in combination with fludarabine andin most cases also with thiotepa.
The apparent volume of distribution of thiotepa appears independent of the administered dose.
Thiotepa was shown to be genotoxic in vitro and in vivo, and carcinogenic in mice and rats.
The CHMP noted that the active substance in Tepadina, thiotepa, has a well established used.
Thiotepa is a polyfunctional cytotoxic agent related chemically and pharmacologically to the nitrogen mustard.
Therefore it can be concluded that conditioning treatments including thiotepa are myeloablative.
Treosulfan is given in combination with fludarabine, with thiotepa(intensified regimen; FT10-14TT regimen) or without thiotepa(FT10-14 regimen).
The results of published clinical studies supporting the efficacy of thiotepa are summarised.
Alkylating chemotherapeutic agents,including thiotepa, inhibit plasma pseudocholinesterase by 35% to 70%.
TEPADINA is a white crystalline powder supplied in a glass vial containing 15 mg thiotepa.